OACC
Oaktree Acquisition Corp. III Life Sciences
Shell Companies
Market Cap$261M
5Y Perf.+6.5%
Compare Stocks
4 / 10Try these comparisons:
Stock Comparison
OACC vs RLAY vs RXRX vs BEAM
Revenue, margins, valuation, and 5-year total return — side by side.
RLAY
Relay Therapeutics, Inc.
Biotechnology
Market Cap$2.37B
5Y Perf.+203.6%
RXRX
Recursion Pharmaceuticals, Inc.
Biotechnology
Market Cap$1.46B
5Y Perf.-51.6%
BEAM
Beam Therapeutics Inc.
Biotechnology
Market Cap$3.23B
5Y Perf.+26.9%
OACC vs RLAY vs RXRX vs BEAM — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | OACC | RLAY | RXRX | BEAM |
|---|---|---|---|---|
| Industry | Shell Companies | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $261M | $2.37B | $1.46B | $3.23B |
| Revenue (TTM) | $0.00 | $11M | $66M | $132M |
| Net Income (TTM) | $5M | $-273M | $-560M | $-65M |
| Gross Margin | — | 66.3% | -34.4% | -64.2% |
| Operating Margin | — | -27.8% | -8.8% | -281.0% |
| Forward P/E | 195.8x | — | — | — |
| Total Debt | $12K | $32M | $78M | $294M |
| Cash & Equiv. | $1M | $84M | $743M | $295M |
OACC vs RLAY vs RXRX vs BEAM — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
OACC
RLAY
RXRX
BEAM
| Stock | Dec 24 | May 26 | Return |
|---|---|---|---|
| Oaktree Acquisition… (OACC) | 100 | 106.5 | +6.5% |
| Relay Therapeutics,… (RLAY) | 100 | 303.6 | +203.6% |
| Recursion Pharmaceu… (RXRX) | 100 | 48.4 | -51.6% |
| Beam Therapeutics I… (BEAM) | 100 | 126.9 | +26.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: OACC vs RLAY vs RXRX vs BEAM
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: OACC leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Relay Therapeutics, Inc. is the stronger pick specifically for recent price momentum and sentiment. BEAM also leads in specific categories worth noting. This set spans 2 sectors — these stocks serve different portfolio roles, not just different price points.
OACC
Oaktree Acquisition Corp. III Life Sciences
The Banking Pick
OACC carries the broadest edge in this set and is the clearest fit for income & stability and sleep-well-at-night.
- beta 0.08
- Lower volatility, beta 0.08, Low D/E 0.0%, current ratio 2.14x
- 0.8% margin vs RLAY's -25.5%
- Beta 0.08 vs RXRX's 3.18, lower leverage
Best for: income & stability and sleep-well-at-night
RLAY
Relay Therapeutics, Inc.
The Defensive Pick
RLAY is the #2 pick in this set and the best alternative if defensive is your priority.
- Beta 1.77, current ratio 22.61x
- +324.1% vs RXRX's -22.0%
Best for: defensive
RXRX
Recursion Pharmaceuticals, Inc.
The Growth Angle
RXRX lags the leaders in this set but could rank higher in a more targeted comparison.
Best for: healthcare exposure
BEAM
Beam Therapeutics Inc.
The Growth Play
BEAM is the clearest fit if your priority is growth exposure and long-term compounding.
- Rev growth 120.0%, EPS growth 82.3%, 3Y rev CAGR 31.9%
- 67.8% 10Y total return vs OACC's 6.1%
- 120.0% revenue growth vs RXRX's 26.9%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BEAM | 120.0% revenue growth vs RXRX's 26.9% |
| Quality / Margins | OACC | 0.8% margin vs RLAY's -25.5% |
| Stability / Safety | OACC | Beta 0.08 vs RXRX's 3.18, lower leverage |
| Dividends | Tie | None of these 4 stocks pay a meaningful dividend |
| Momentum (1Y) | RLAY | +324.1% vs RXRX's -22.0% |
| Efficiency (ROA) | OACC | 2.6% ROA vs RXRX's -40.6% |
OACC vs RLAY vs RXRX vs BEAM — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
FY 2025
Segment breakdown not available.
OACC vs RLAY vs RXRX vs BEAM — Financial Metrics
Side-by-side numbers across 4 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLOACCLAGGINGBEAM
Who Leads Where
OACC leads in 2 of 6 categories
BEAM leads 1 • RXRX leads 1 • RLAY leads 1
Explore the data ↓BEAMBeam Therapeutics Inc.
1leads
RXRXRecursion Pharmaceuti…
1leads
RLAYRelay Therapeutics, I…
1leads
OACCOaktree Acquisition C…
2leads
6 Total Categories
CATEGORYLEADERvs RLAYvs RXRXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
BEAM3/6
Valuation MetricsMultiples, price ratios, and targets
RXRX2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
OACC5/9
Total Returns1Y, 3Y, 5Y total returns with dividends
RLAY4/6
Risk & VolatilityBeta, volatility, and downside exposure
OACC2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
BEAM leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
BEAM and OACC operate at a comparable scale, with $132M and $0 in trailing revenue. Profitability is closely matched — net margins range from -49.2% (BEAM) to -25.5% (RLAY). On growth, RXRX holds the edge at -56.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | OACCOaktree Acquisiti… | RLAYRelay Therapeutic… | RXRXRecursion Pharmac… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $11M | $66M | $132M |
| EBITDAEarnings before interest/tax | -$847,195 | -$298M | -$521M | -$355M |
| Net IncomeAfter-tax profit | $5M | -$273M | -$560M | -$65M |
| Free Cash FlowCash after capex | -$278,200 | -$213M | -$326M | -$384M |
| Gross MarginGross profit ÷ Revenue | — | +66.3% | -34.4% | -64.2% |
| Operating MarginEBIT ÷ Revenue | — | -27.8% | -8.8% | -2.8% |
| Net MarginNet income ÷ Revenue | — | -25.5% | -8.4% | -49.2% |
| FCF MarginFCF ÷ Revenue | — | -20.0% | -4.9% | -2.9% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -60.9% | -56.1% | -100.0% |
| EPS Growth (YoY)Latest quarter vs prior year | — | +10.9% | +56.0% | +26.6% |
BEAM leads this category, winning 3 of 6 comparable metrics.
Valuation Metrics
RXRX leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | OACCOaktree Acquisiti… | RLAYRelay Therapeutic… | RXRXRecursion Pharmac… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| Market CapShares × price | $261M | $2.4B | $1.5B | $3.2B |
| Enterprise ValueMkt cap + debt − cash | $259M | $2.3B | $797M | $3.2B |
| Trailing P/EPrice ÷ TTM EPS | 195.76x | -7.77x | -2.27x | -38.85x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — |
| EV / EBITDAEnterprise value multiple | 9999.00x | — | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 154.15x | 19.58x | 23.14x |
| Price / BookPrice ÷ Book value/share | 1.39x | 3.79x | 1.29x | 2.51x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — |
RXRX leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
OACC leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
OACC delivers a 0.0% return on equity — every $100 of shareholder capital generates $0 in annual profit, vs $-54 for RXRX. OACC carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to BEAM's 0.24x. On the Piotroski fundamental quality scale (0–9), RLAY scores 5/9 vs BEAM's 4/9, reflecting solid financial health.
| Metric | OACCOaktree Acquisiti… | RLAYRelay Therapeutic… | RXRXRecursion Pharmac… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| ROE (TTM)Return on equity | +0.0% | -43.9% | -54.3% | -5.9% |
| ROA (TTM)Return on assets | +2.6% | -40.1% | -40.6% | -4.6% |
| ROICReturn on invested capital | — | -37.3% | -95.8% | -31.1% |
| ROCEReturn on capital employed | -0.0% | -42.7% | -50.1% | -33.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.00x | 0.06x | 0.07x | 0.24x |
| Net DebtTotal debt minus cash | -$1M | -$52M | -$665M | -$1M |
| Cash & Equiv.Liquid assets | $1M | $84M | $743M | $295M |
| Total DebtShort + long-term debt | $11,824 | $32M | $78M | $294M |
| Interest CoverageEBIT ÷ Interest expense | — | — | -336.46x | 1.08x |
OACC leads this category, winning 5 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
RLAY leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in OACC five years ago would be worth $10,610 today (with dividends reinvested), compared to $1,179 for RXRX. Over the past 12 months, RLAY leads with a +324.1% total return vs RXRX's -22.0%. The 3-year compound annual growth rate (CAGR) favors RLAY at 5.0% vs RXRX's -16.4% — a key indicator of consistent wealth creation.
| Metric | OACCOaktree Acquisiti… | RLAYRelay Therapeutic… | RXRXRecursion Pharmac… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| YTD ReturnYear-to-date | -0.0% | +52.9% | -22.1% | +16.0% |
| 1-Year ReturnPast 12 months | +1.4% | +324.1% | -22.0% | +93.9% |
| 3-Year ReturnCumulative with dividends | +6.1% | +15.6% | -41.6% | -5.6% |
| 5-Year ReturnCumulative with dividends | +6.1% | -57.6% | -88.2% | -55.6% |
| 10-Year ReturnCumulative with dividends | +6.1% | -64.3% | -81.8% | +67.8% |
| CAGR (3Y)Annualised 3-year return | +2.0% | +5.0% | -16.4% | -1.9% |
RLAY leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
OACC leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
OACC is the less volatile stock with a 0.08 beta — it tends to amplify market swings less than RXRX's 3.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. OACC currently trades 98.8% from its 52-week high vs RXRX's 45.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | OACCOaktree Acquisiti… | RLAYRelay Therapeutic… | RXRXRecursion Pharmac… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.08x | 1.77x | 3.18x | 2.14x |
| 52-Week HighHighest price in past year | $10.74 | $17.31 | $7.18 | $36.44 |
| 52-Week LowLowest price in past year | $10.30 | $2.67 | $2.80 | $15.35 |
| % of 52W HighCurrent price vs 52-week peak | +98.8% | +72.3% | +45.5% | +86.4% |
| RSI (14)Momentum oscillator 0–100 | 47.6 | 45.9 | 49.5 | 60.9 |
| Avg Volume (50D)Average daily shares traded | 38K | 3.1M | 12.5M | 2.0M |
OACC leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: RLAY as "Buy", RXRX as "Hold", BEAM as "Buy". Consensus price targets imply 236.4% upside for RXRX (target: $11) vs 29.7% for BEAM (target: $41).
| Metric | OACCOaktree Acquisiti… | RLAYRelay Therapeutic… | RXRXRecursion Pharmac… | BEAMBeam Therapeutics… |
|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy | Hold | Buy |
| Price TargetConsensus 12-month target | — | $21.60 | $11.00 | $40.83 |
| # AnalystsCovering analysts | — | 15 | 10 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
OACC leads in 2 of 6 categories (Profitability & Efficiency, Risk & Volatility). BEAM leads in 1 (Income & Cash Flow).
Best OverallOaktree Acquisition Corp. I… (OACC)Leads 2 of 6 categories
Loading custom metrics...
OACC vs RLAY vs RXRX vs BEAM: Key Questions Answered
8 questions · data-driven answers · updated daily
01Is OACC or RLAY or RXRX or BEAM a better buy right now?
For growth investors, Beam Therapeutics Inc.
(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus 26. 9% for Recursion Pharmaceuticals, Inc. (RXRX). Oaktree Acquisition Corp. III Life Sciences (OACC) offers the better valuation at 195. 8x trailing P/E, making it the more compelling value choice. Analysts rate Relay Therapeutics, Inc. (RLAY) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — OACC or RLAY or RXRX or BEAM?
Over the past 5 years, Oaktree Acquisition Corp.
III Life Sciences (OACC) delivered a total return of +6. 1%, compared to -88. 2% for Recursion Pharmaceuticals, Inc. (RXRX). Over 10 years, the gap is even starker: BEAM returned +67. 8% versus RXRX's -81. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — OACC or RLAY or RXRX or BEAM?
By beta (market sensitivity over 5 years), Oaktree Acquisition Corp.
III Life Sciences (OACC) is the lower-risk stock at 0. 08β versus Recursion Pharmaceuticals, Inc. 's 3. 18β — meaning RXRX is approximately 3817% more volatile than OACC relative to the S&P 500. On balance sheet safety, Oaktree Acquisition Corp. III Life Sciences (OACC) carries a lower debt/equity ratio of 0% versus 24% for Beam Therapeutics Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — OACC or RLAY or RXRX or BEAM?
By revenue growth (latest reported year), Beam Therapeutics Inc.
(BEAM) is pulling ahead at 120. 0% versus 26. 9% for Recursion Pharmaceuticals, Inc. (RXRX). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to 14. 8% for Recursion Pharmaceuticals, Inc.. Over a 3-year CAGR, RLAY leads at 123. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — OACC or RLAY or RXRX or BEAM?
Oaktree Acquisition Corp.
III Life Sciences (OACC) is the more profitable company, earning 0. 0% net margin versus -1800. 6% for Relay Therapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: OACC leads at 0. 0% versus -1971. 6% for RLAY. At the gross margin level — before operating expenses — BEAM leads at 84. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — OACC or RLAY or RXRX or BEAM?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is OACC or RLAY or RXRX or BEAM better for a retirement portfolio?
For long-horizon retirement investors, Oaktree Acquisition Corp.
III Life Sciences (OACC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 08)). Recursion Pharmaceuticals, Inc. (RXRX) carries a higher beta of 3. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (OACC: +6. 1%, RXRX: -81. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between OACC and RLAY and RXRX and BEAM?
These companies operate in different sectors (OACC (Financial Services) and RLAY (Healthcare) and RXRX (Healthcare) and BEAM (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: OACC is a small-cap quality compounder stock; RLAY is a small-cap high-growth stock; RXRX is a small-cap high-growth stock; BEAM is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.